Your browser is no longer supported. Please, upgrade your browser.
UMRX Unum Therapeutics Inc. monthly Stock Chart
UMRX [NASD]
Unum Therapeutics Inc.
Index- P/E- EPS (ttm)-1.41 Insider Own36.91% Shs Outstand27.50M Perf Week27.62%
Market Cap13.06M Forward P/E- EPS next Y-0.74 Insider Trans0.00% Shs Float18.86M Perf Month-28.24%
Income-42.70M PEG- EPS next Q-0.29 Inst Own32.50% Short Float1.84% Perf Quarter-35.33%
Sales11.00M P/S1.19 EPS this Y-60.60% Inst Trans-23.04% Short Ratio1.38 Perf Half Y-70.86%
Book/sh0.93 P/B0.51 EPS next Y47.50% ROA-58.10% Target Price6.50 Perf Year-89.23%
Cash/sh1.67 P/C0.28 EPS next 5Y- ROE-96.10% 52W Range0.30 - 4.87 Perf YTD-34.05%
Dividend- P/FCF- EPS past 5Y- ROI-59.80% 52W High-90.25% Beta-
Dividend %- Quick Ratio2.00 Sales past 5Y- Gross Margin- 52W Low58.33% ATR0.10
Employees56 Current Ratio2.00 Sales Q/Q-50.00% Oper. Margin- RSI (14)45.67 Volatility30.48% 25.78%
OptionableNo Debt/Eq0.00 EPS Q/Q-14.30% Profit Margin- Rel Volume1.52 Prev Close0.51
ShortableYes LT Debt/Eq0.00 EarningsMar 26 Payout- Avg Volume251.59K Price0.47
Recom2.70 SMA205.82% SMA50-30.82% SMA200-64.76% Volume383,667 Change-6.03%
Mar-04-20Downgrade Wedbush Outperform → Neutral
Mar-03-20Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-20-18Initiated H.C. Wainwright Buy $18
Mar-26-20 08:45AM  Unum Therapeutics Inc. (UMRX) Q4 Earnings and Revenues Beat Estimates Zacks
07:30AM  Unum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Updates GlobeNewswire
Mar-20-20 07:30AM  Unum Therapeutics Announces Common Stock Purchase Agreement for up to $25 Million with Lincoln Park Capital GlobeNewswire
Mar-19-20 12:30PM  Unum Therapeutics Inc. (UMRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks +9.09%
Mar-02-20 08:45AM  Unum Therapeutics Implements Strategic Restructuring to Prioritize Efforts on BOXR1030 for the Treatment of Solid Tumor Cancers GlobeNewswire -17.82%
Jan-29-20 07:05AM  Unum Therapeutics Provides Updates to its Phase 1 Trial of ACTR707 for HER2+ Solid Tumor Cancers GlobeNewswire -10.63%
Jan-17-20 01:56PM  Did Changing Sentiment Drive Unum Therapeutics's (NASDAQ:UMRX) Share Price Down A Painful 77%? Simply Wall St.
Dec-22-19 05:09PM  Hedge Funds Are Selling Unum Therapeutics Inc. (UMRX) Insider Monkey
Dec-07-19 02:45PM  Unum Therapeutics Announces New Data at the American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Nov-15-19 07:30AM  Unum Therapeutics to Present at Upcoming Investor Conference GlobeNewswire -21.29%
Nov-12-19 06:15PM  Unum Therapeutics Inc. (UMRX) Reports Q3 Loss, Misses Revenue Estimates Zacks -6.78%
04:30PM  Unum Therapeutics Reports Third Quarter 2019 Financial Results GlobeNewswire
Nov-05-19 08:30AM  Unum Therapeutics Presents Preclinical Data for BOXR1030 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire -9.79%
Nov-04-19 04:00PM  Unum Therapeutics Announces Strategic Focus on Developing Best-in-Class Cellular Therapies for Solid Tumor Cancers GlobeNewswire +5.93%
10:30AM  Unum Therapeutics Inc. (UMRX) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Oct-03-19 02:26PM  Here's Why We're Watching Unum Therapeutics's (NASDAQ:UMRX) Cash Burn Situation Simply Wall St. +5.88%
Oct-02-19 07:05AM  Unum Therapeutics Announces Data Presentation at the Upcoming Society for Immunotherapy of Cancer (SITC) Meeting GlobeNewswire
Sep-03-19 02:21PM  In expense-laden biotech industry, here are the Mass. startups most in need of cash American City Business Journals -9.38%
Aug-26-19 07:05AM  Unum Therapeutics to Present at Upcoming September Investor Conferences GlobeNewswire +5.26%
Aug-20-19 12:54AM  Edited Transcript of UMRX earnings conference call or presentation 12-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-12-19 05:25PM  Unum Therapeutics Inc. (UMRX) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM  Unum Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Updates GlobeNewswire
02:30PM  Unum Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
10:59AM  Amicus (FOLD) Q2 Earnings Match, Stock Falls on Weak Q3 View Zacks
Aug-02-19 09:00AM  Unum Therapeutics to Review Second Quarter 2019 Financial Results on August 12, 2019 GlobeNewswire -12.45%
Jul-31-19 02:08PM  Those Who Purchased Unum Therapeutics (NASDAQ:UMRX) Shares A Year Ago Have A 87% Loss To Show For It Simply Wall St.
Jul-29-19 01:26PM  Amid FDA hold, Unum says chief medical officer will stay involved for 2 years American City Business Journals
07:05AM  Unum Therapeutics Announces New Appointments to its Board of Directors GlobeNewswire
Jul-19-19 07:44AM  Unum Therapeutics' Shares March Higher, Can It Continue? Zacks
Jul-17-19 09:00AM  Unum Therapeutics to Present at the Wedbush PacGrow Healthcare Conference GlobeNewswire
Jul-03-19 10:43AM  FDA Places Unum's Early Stage Cancer Drug Trial On Clinical Hold Benzinga
08:59AM  Unum Therapeutics Stock Dives After Cancer Drug Trial Is Suspended Barrons.com
08:21AM  Unum Therapeutics stock plunges toward record low after FDA places 'clinical hold' on trial MarketWatch
Jul-02-19 04:30PM  Unum Therapeutics Announces Regulatory Update from Phase 1 Trial with ACTR087 GlobeNewswire -9.13%
Jun-13-19 06:06PM  Unum Therapeutics Strengthens and Expands Leadership Team GlobeNewswire
May-25-19 01:25AM  Edited Transcript of UMRX earnings conference call or presentation 13-May-19 12:00pm GMT Thomson Reuters StreetEvents
May-13-19 08:25AM  Unum Therapeutics Inc. (UMRX) Reports Q1 Loss, Misses Revenue Estimates Zacks -6.41%
07:00AM  Unum Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
May-07-19 10:38AM  Will Life Sciences Sales Boost Bio-Rad's (BIO) Q1 Earnings? Zacks
May-06-19 10:30AM  Unum Therapeutics Inc. (UMRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
07:00AM  Unum Therapeutics to Host First Quarter 2019 Financial Results Conference Call and Webcast on May 13, 2019 at 8:00 A.M. ET GlobeNewswire
05:07AM  Can Epidolex Drive GW Pharmaceuticals' (GWPH) Q2 Earnings? Zacks
Apr-28-19 10:51AM  What Kind Of Shareholder Owns Most Unum Therapeutics Inc. (NASDAQ:UMRX) Stock? Simply Wall St.
Apr-02-19 10:23PM  Edited Transcript of UMRX earnings conference call or presentation 28-Mar-19 12:00pm GMT Thomson Reuters StreetEvents
07:00AM  Unum Therapeutics to Present at Two Upcoming Investor Conferences GlobeNewswire
Mar-28-19 07:00AM  Unum Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update GlobeNewswire +8.62%
Mar-21-19 07:00AM  Unum Therapeutics to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast on March 28, 2019 at 8:00 A.M. ET GlobeNewswire
Jan-04-19 06:15PM  CORRECTING and REPLACING -- Unum Therapeutics Announces 2019 Goals and Expected Milestones GlobeNewswire
Jan-03-19 07:00AM  Unum Therapeutics Announces Transition of Chief Financial Officer GlobeNewswire
07:00AM  Unum Therapeutics Announces 2019 Goals and Expected Milestones GlobeNewswire
Dec-20-18 07:00AM  Unum Therapeutics Added to NASDAQ Biotechnology Index GlobeNewswire
Dec-10-18 07:30AM  New Research Coverage Highlights Synopsys, Unum Therapeutics, HD Supply, Tech Data, Mellanox Technologies, and eHealth Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire -5.10%
Dec-08-18 09:58PM  Hedge Funds Are Selling Paratek Pharmaceuticals Inc (PRTK) Insider Monkey
Dec-06-18 07:00AM  Unum Therapeutics Announces US Patent Protection for ACTR Technology GlobeNewswire
Dec-02-18 09:00PM  Unum Therapeutics Presents Preliminary Results from Ongoing Phase 1 Study ATTCK-20-03 at the 2018 ASH Annual Meeting GlobeNewswire
Dec-01-18 09:25PM  Unum Therapeutics Presents Preliminary Results from Ongoing Phase 1 Study ATTCK-17-01 at the 2018 ASH Annual Meeting GlobeNewswire
Nov-12-18 05:55PM  Edited Transcript of UMRX earnings conference call or presentation 12-Nov-18 9:30pm GMT Thomson Reuters StreetEvents -5.42%
04:01PM  Unum Therapeutics to Host Investor Event on its Efforts to Realize the Promise of T Cell Therapies in Solid Tumors GlobeNewswire
04:01PM  Unum Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Nov-09-18 02:31PM  Unum Therapeutics to Present Preclinical Data on Applications of ACTR Proprietary Technology Platform in Solid Tumors at the San Antonio Breast Cancer Symposium GlobeNewswire -5.02%
Nov-06-18 08:01AM  Unum Therapeutics to Present Preclinical Data on a New, Emerging Platform Technology for Solid Tumors at the SITC Annual Meeting GlobeNewswire
Nov-05-18 07:00AM  Unum Therapeutics to Host Third Quarter 2018 Financial Results Conference Call and Webcast on November 12, 2018 at 4:30 P.M. ET GlobeNewswire -5.10%
Nov-01-18 09:01AM  Unum Therapeutics to Present Preliminary Results from Ongoing Phase 1 Studies ATTCK-20-03 and ATTCK-17-01 at the 2018 ASH Annual Meeting GlobeNewswire +7.35%
07:40AM  Report: Developing Opportunities within Waste Management, Cubic, Unum Therapeutics, Highwoods Properties, Trinity Industries, and Cerner Future Expectations, Projections Moving into 2018 GlobeNewswire
Sep-17-18 07:00AM  Unum Therapeutics Announces Abstract Accepted for Presentation at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference GlobeNewswire
Sep-07-18 07:00AM  Unum Therapeutics to Present at Morgan Stanley 16th Annual Global Healthcare Conference GlobeNewswire
Aug-29-18 10:01PM  Edited Transcript of UMRX earnings conference call or presentation 13-Aug-18 9:00pm GMT Thomson Reuters StreetEvents +9.38%
Aug-13-18 04:05PM  Unum Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
04:05PM  Unum Therapeutics Announces Active Investigational New Drug (IND) Application for Antibody-Coupled T Cell Receptor (ACTR) platform in Combination with Trastuzumab in Patients with HER2+ Advanced Cancers GlobeNewswire
03:00PM  Unum Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-08-18 07:00AM  Unum Therapeutics to Present at Two Upcoming Investor Conferences GlobeNewswire -9.90%
Aug-06-18 07:00AM  Unum Therapeutics to Host Second Quarter 2018 Financial Results Conference Call and Webcast on August 13, 2018 at 5:00 P.M. ET GlobeNewswire +6.61%
Jul-12-18 07:00AM  Unum Therapeutics to Present Pre-Clinical Data on its Antibody-Coupled T Cell Receptor (ACTR) Platform at the American Society of Hematology (ASH) Summit on Emerging Immunotherapies for Hematological Diseases GlobeNewswire
Jun-25-18 07:00AM  Unum Therapeutics Joins Russell 3000® Index GlobeNewswire
Jun-11-18 08:05AM  Unum Therapeutics, Progress After IPO, Clinical Status, Analysts Review and Target ACCESSWIRE
May-14-18 07:00AM  Unum Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Apr-03-18 05:00PM  Unum Therapeutics Announces Closing of Initial Public Offering and Concurrent Private Placement with Seattle Genetics GlobeNewswire
Unum Therapeutics Inc., a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL). Its product portfolio also includes ACTR087 used in combination with rituximab that is in Phase I clinical trials to treat adult patients with r/r NHL; ACTR087 used in combination with SEA-BCMA, which is in Phase I clinical trials for treating patients with r/r multiple myeloma; ACTR707 used in combination with trastuzumab that is in Phase I clinical trials for treating HER2+ solid tumor cancers; and BOXR1030, which is in pre-clinical stage, targets GPC3, an oncofetal antigen expressed in various tumors, including liver and lung cancers. Unum Therapeutics Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.